Sign Up to like & get
recommendations!
0
Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.20263
Abstract: LMB-100 (RG7787) is a recombinant immunotoxin, which kills mesothelin-expressing cancer cells and now being evaluated in phase 1 trials. To enhance the anti-tumor activity of LMB-100, we have searched for agents, already approved for cancer…
read more here.
Keywords:
decreases cflip;
panbinostat decreases;
lmb 100;
pathway ... See more keywords